Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WA › Monroe › NPI 1013074061
Hospital

Public Hospital District 1 of Snohomish County

Public Hospital District 1 of Snohomish County was paid $11.26M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 16% of everything it billed.

33Billing provider infoPUBLIC HOSPITAL DISTRICT 1 OF SNOHOMISH COUNTY
MONROE, WA 98272
33aNPI1013074061assigned 01/02/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.26M
24GClaims325,304
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Washington

Rank by total paid#33 of 49
Median peer was paid$20.06M
This provider vs. median0.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201845,161$1.47M
201941,672$1.30M
202035,490$1.07M
202141,946$1.25M
202254,911$1.52M
202356,553$2.10M
2024incomplete49,571$2.56M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
96361 Intravenous infusion, hydration; each additional hour 16% 7,158 6,391 $1.85M
H0018 Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem 14% 5,000 458 $1.54M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 13% 13,084 12,021 $1.47M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 12% 11,283 10,594 $1.37M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 11% 11,571 10,568 $1.28M
74177 Computed tomography, abdomen and pelvis; with contrast material 6.1% 2,860 2,714 $682K
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.9% 3,295 3,146 $327K
70450 Computed tomography, head or brain; without contrast material 2.8% 2,242 2,102 $318K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.2% 11,131 3,730 $249K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 2.0% 1,604 1,453 $231K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.9% 3,067 2,730 $218K
80053 Comprehensive metabolic panel <1% 17,694 14,705 $107K
169 more codes
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 6,092 $106K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,463 $83K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 418 $82K
71275 Computed tomographic angiography, chest, with contrast material <1% 434 $78K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 22,365 $71K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 1,302 $71K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 7,986 $57K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 600 $55K
84484 <1% 7,405 $52K
G0378 Hospital observation service, per hour <1% 807 $46K
96375 Therapeutic injection; each additional sequential IV push <1% 7,229 $45K
97161 <1% 861 $38K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 8,455 $37K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 3,042 $34K
84443 Thyroid stimulating hormone (TSH) <1% 4,091 $32K
71045 Radiologic examination, chest; single view <1% 4,182 $30K
71046 Radiologic examination, chest; 2 views <1% 2,381 $30K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 4,570 $29K
36415 Collection of venous blood by venipuncture <1% 14,591 $24K
83690 <1% 7,300 $24K
83605 <1% 4,018 $23K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 983 $23K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 141 $23K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 349 $23K
96164 <1% 1,169 $22K
83880 <1% 2,282 $22K
80048 Basic metabolic panel (calcium, ionized) <1% 4,180 $21K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 118 $20K
96165 <1% 1,169 $20K
76830 Ultrasound, transvaginal <1% 216 $19K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 1,150 $19K
80305 <1% 3,780 $17K
87086 Culture, bacterial; quantitative colony count, urine <1% 4,222 $16K
83036 Hemoglobin; glycosylated (A1C) <1% 2,589 $15K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 130 $15K
81001 <1% 11,446 $15K
70496 <1% 60 $14K
72125 Computed tomography, cervical spine; without contrast material <1% 428 $13K
80061 Lipid panel <1% 1,715 $12K
96376 <1% 2,211 $11K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 581 $10K
84703 <1% 2,625 $10K
87040 <1% 1,007 $8K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,402 $8K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 644 $8K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 74 $7K
76801 <1% 148 $7K
82077 <1% 1,137 $7K
83735 <1% 3,910 $7K
70498 <1% 59 $7K
73610 <1% 362 $6K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 594 $6K
90715 <1% 366 $6K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 24 $6K
84702 <1% 842 $6K
73630 <1% 330 $6K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 581 $6K
85378 <1% 520 $5K
85610 <1% 2,658 $5K
87077 <1% 1,400 $5K
87186 <1% 1,245 $4K
J7050 Infusion, normal saline solution, 250 cc <1% 1,307 $4K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 660 $4K
81025 <1% 2,079 $4K
93971 <1% 41 $4K
J7120 Ringers lactate infusion, up to 1000 cc <1% 1,912 $4K
82728 <1% 295 $4K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,644 $3K
93975 <1% 27 $3K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 4,944 $3K
J1170 Injection, hydromorphone, up to 4 mg <1% 2,764 $3K
86803 <1% 253 $3K
73564 <1% 190 $3K
85027 <1% 436 $3K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,731 $3K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 312 $3K
J7030 Infusion, normal saline solution , 1000 cc <1% 2,174 $3K
99232 Hospital visit by a doctor, follow-up day <1% 102 $2K
J2270 Injection, morphine sulfate, up to 10 mg <1% 2,943 $2K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 394 $2K
73030 <1% 128 $2K
85379 <1% 458 $2K
12001 <1% 12 $2K
H0004 Behavioral health counseling and therapy, per 15 minutes <1% 19 $2K
J0690 Injection, cefazolin sodium, 500 mg <1% 682 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 440 $2K
80047 <1% 364 $2K
84439 <1% 275 $2K
77067 Screening mammography, bilateral, including computer-aided detection <1% 26 $2K
86900 <1% 397 $1K
86901 <1% 564 $1K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 1,327 $1K
86850 <1% 347 $1K
86592 <1% 217 $1K
73130 <1% 77 $1K
73110 <1% 78 $1K
81003 <1% 806 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,571 $912.25
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 373 $904.57
J2060 Injection, lorazepam, 2 mg <1% 1,580 $865.81
85730 <1% 1,056 $814.97
86140 <1% 236 $752.79
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,577 $738.52
77063 Screening digital breast tomosynthesis, bilateral <1% 26 $692.86
99222 Initial hospital care, per day, moderate complexity <1% 14 $672.39
82805 <1% 81 $637.70
82948 <1% 1,158 $637.13
82962 <1% 945 $609.95
87634 <1% 286 $604.48
85652 <1% 236 $594.99
99239 Hospital discharge day management, more than 30 minutes <1% 14 $577.16
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 16 $561.37
96368 <1% 24 $556.89
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 897 $543.47
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 27 $508.95
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,137 $498.34
99214 Doctor's office visit, returning patient (more involved) <1% 24 $475.14
0240U <1% 572 $463.70
87070 <1% 92 $460.34
J3475 Injection, magnesium sulfate, per 500 mg <1% 374 $425.18
97162 <1% 12 $386.08
85651 <1% 160 $378.97
80076 <1% 60 $346.74
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 1,921 $338.61
99213 Doctor's office visit, returning patient (routine) <1% 28 $315.51
72131 <1% 17 $304.11
82553 <1% 36 $292.39
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 287 $288.45
72128 <1% 13 $270.23
82565 <1% 327 $224.74
82550 <1% 150 $212.13
87075 <1% 27 $207.41
J2704 Injection, propofol, 10 mg <1% 216 $199.84
80050 General health panel <1% 31 $173.60
82803 <1% 63 $165.91
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 322 $161.33
87340 <1% 52 $144.41
87088 <1% 40 $142.64
87205 <1% 55 $124.41
83540 <1% 14 $117.95
83550 <1% 13 $115.64
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 40 $106.86
85014 <1% 93 $95.45
86780 <1% 15 $92.09
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 12 $88.37
86762 <1% 27 $83.99
85018 <1% 119 $78.53
J3370 Injection, vancomycin hcl, 500 mg <1% 59 $73.26
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 15 $70.57
J0780 Injection, prochlorperazine, up to 10 mg <1% 43 $64.76
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 31 $57.47
94760 <1% 279 $53.15
84100 <1% 47 $49.37
82248 <1% 27 $40.09
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 89 $36.55
J1171 Injection, hydromorphone, 0.1 mg <1% 54 $33.82
A9270 Non-covered item or service <1% 12,772 $22.47
82009 <1% 12 $22.14
J1650 Injection, enoxaparin sodium, 10 mg <1% 26 $21.23
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 54 $17.42
36000 <1% 369 $17.07
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 659 $9.20
J1630 Injection, haloperidol, up to 5 mg <1% 13 $6.60
A9575 Injection, gadoterate meglumine, 0.1 ml <1% 28 $1.93
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 26 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 24 $0.00
94761 0% 228 $0.00
87154 0% 78 $0.00
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme 0% 52 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLAPLANTE, LISA (CHIEF ADMINISTRATIVE OFFICER)